Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Four-Arm Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of 3 Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS) Over a 36 Week Treatment Course

NCT00642902 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT00642902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00642902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Four-Arm Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of 3 Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS) Over a 36 Week Treatment Course
Lead sponsor
EMD Serono
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2008
Completion date
September 30, 2009
Enrollment
255 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis